References

nnp

Neurology, Neuropsychiatry, Psychosomatics

Неврология, нейропсихиатрия, психосоматика

2074-27112310-1342

"IMA-Press", LLC

10.14412/2074-2711-2023-5-102-108

nnp-2111

Research Article

REVIEWS

ОБЗОРЫ

Migraine in perimenopausal women

Мигрень у женщин в перименопаузальном периоде

https://orcid.org/0009-0007-3192-1936

Климентова

Д. А.

Klimentova

D. A.

Диана Андреевна Климентова - кафедра нервных болезней и нейрохирургии.

119021, Москва, ул. Россолимо, 11, стр. 1

Diana Andreevna Klimentova

11, Rossolimo St., Build. 1, Moscow 119021

klimentovadiana23@gmail.com

https://orcid.org/0000-0002-3833-532X

Табеева

Г. Р.

Tabeeva

G. R.

119021, Москва, ул. Россолимо, 11, стр. 1

11, Rossolimo St., Build. 1, Moscow 119021

Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)»РоссияN.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation

2023

23102023

155102108

2023

Климентова Д.А., Табеева Г.Р.

Klimentova D.A., Tabeeva G.R.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://nnp.ima-press.net/nnp/article/view/2111

Sex hormones have a significant influence on the course of migraine in women. Perimenopause is accompanied by unstable cycle length, vasomotor, urogenital and other symptoms, while the course of migraine usually worsens. In postmenopause ovarian follicular function decreases, and the course of migraine improves in most cases. However, a number of studies have shown that the course of migraine does not change or even worsen after menopause. Perimenopausal and postmenopausal migraine patients are also more likely to suffer from vasomotor symptoms. Hormone replacement therapy is prescribed to relieve vasomotor symptoms, which may worsen the course of migraine. In this review, the influence of perimenopause and postmenopause on the course of migraine, the use of hormone replacement therapy, and methods to relieve and prevent attacks in patients with migraine are examined in detail.

Половые гормоны оказывают существенное влияние на течение мигрени у женщин. Период перименопаузы сопровождается нестабильной продолжительностью цикла, вазомоторными, урогенитальными и другими симптомами, при этом течение мигрени, как правило, усугубляется. В постменопаузе угасает фолликулярная функция яичников, течение мигрени в большинстве случаев улучшается. Однако в ходе ряда исследований было показано, что течение мигрени после менопаузы не меняется либо усугубляется. Также пациентки с мигренью в перименопаузе и постменопаузе чаще страдают от вазомоторных симптомов. Для купирования вазомоторных симптомов назначается заместительная гормональная терапия, которая может усугублять течение мигрени. В данном обзоре будут подробно рассмотрены вопросы влияния перименопаузы и постменопаузы на течение мигрени, вопросы применения гормональной заместительной терапии, методы купирования и профилактики приступов у пациенток с мигренью.

мигреньперименопаузаменопаузальный переходпостменопаузалечение мигренипрофилактика приступов мигренигормональная заместительная терапияэстроген

migraineperimenopausemenopausal transitionpostmenopausemigraine treatmentprevention of migraine attackshormone replacement therapyestrogen

Исследование не имело спонсорской поддержки

The investigation has not been sponsored

References1

Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134

Azimova YuE, Amelin AV, Alferova VV, et al. Clinical guidelines “Migraine”. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134 (In Russ.).

MacGregor EA. Menstrual and perimenopausal migraine: A narrative review. Maturitas. 2020 Dec;142:24-30. doi: 10.1016/j.maturitas.2020.07.005. Epub 2020 Jul 10.

Hipolito Rodrigues MA, Maitrot-Mantelet L, Plu-Bureau G, Gompel A. Migraine, hormones and the menopausal transition. Climacteric. 2018 Jun;21(3):256-66. doi: 10.1080/13697137.2018.1439914. Epub 2018 Mar 9.

Harlow SD, Gass M, Hall JE, et al; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012 Apr;19(4):387-95. doi: 10.1097/gme.0b013e31824d8f40

Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x

Oh K, Jung KY, Choi JY, et al. Headaches in middle-aged women during menopausal transition: a headache clinic-based study. Eur Neurol. 2012;68(2):79-83. doi: 10.1159/000336838. Epub 2012 Jul 3.

Ahmad SR, Rosendale N. Sex and Gender Considerations in Episodic Migraine. Curr Pain Headache Rep. 2022 Jul;26(7):505-16. doi: 10.1007/s11916-022-01052-8. Epub 2022 Jun 9.

Карпова МИ, Заряда АА, Долгушина ВФ идр. Мигрень уженщин: клинические итерапевтические аспекты. Журнал неврологии ипсихиатрии им.С.С.Корсакова. 2019;119(3):98-107. doi: 10.17116/jnevro201911903198

Karpova MI, Zariada AA, Dolgushina VF, et al. Migraine in women: clinical and therapeutical aspects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(3):98-107. doi: 10.17116/jnevro201911903198 (In Russ.).

Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x

MacGregor EA, Barnes D. Migraine in a specialist menopause clinic. Climacteric. 1999 Sep;2(3):218-23. doi: 10.3109/13697139909038065

Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache. 2003 Jan;43(1):27-35. doi: 10.1046/j.1526-4610.2003.03005.x

Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073

MacGregor EA. Classification of perimenstrual headache: clinical relevance. Curr Pain Headache Rep. 2012;16(5):452-60 doi: 10.1007/s11916-012-0282-y

Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.

Maleki N, Cheng YC, Tu Y, Locascio JJ. Longitudinal course of vasomotor symptoms in perimenopausal migraineurs. Ann Neurol. 2019 Jun;85(6):865-74. doi: 10.1002/ana.25476. Epub 2019 Apr 30.

Alebna P, Maleki N. Allostatic Load in Perimenopausal Women with Migraine. Front Neurol. 2021 Apr 22;12:649423. doi: 10.3389/fneur.2021.649423

Faubion SS, Ghaith S, Kling JM, et al. Migraine and sleep quality: does the association change in midlife women? Menopause. 2023 Jan 31. doi: 10.1097/GME.0000000000002149. Epub ahead of print.

Makita K, Inagaki M, Kitamura S, Tatsuoka Y. Changes in migraine before and after menopause in Japanese climacteric women. Cephalalgia. 2017 Oct;37(11):1088-92. doi: 10.1177/0333102416653234. Epub 2016 Jun 2.

Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993 Jul;17(1):31-7. doi: 10.1016/03785122(93)90121-w

Kim S, Lee SB, Hong YJ, et al. The influence of endogenous and exogenous hormonal factors on migraine in spontaneous postmenopausal women: A nationwide populationbased study in South Korea. Cephalalgia. 2022 Apr;42(4-5):376-84. doi: 10.1177/03331024211044441. Epub 2021 Sep 27.

Carturan P, Scorcine C, Fragoso YD. Migraine in the post-menopausal period is associated with higher levels of mood disorders, disability, and more menopausal symptoms. Arq Neuropsiquiatr. 2016 Dec;74(12):9991002. doi: 10.1590/0004-282X20160153

Cull RE. Investigation of late-onset migraine. Scott Med J. 1995 Apr;40(2):50-2. doi: 10.1177/003693309504000205

MacDonald CJ, El Fatouhi D, Madika AL, et al. Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study. Neurology. 2021 Jul 6;97(1):e34e41. doi: 10.1212/WNL.0000000000011986. Epub 2021 Apr 21.

Mathes RW, Malone KE, Daling JR, et al. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3116-22. doi: 10.1158/1055-9965.EPI-08-0527

Li CI, Mathes RW, Malone KE, et al. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2030-4. doi: 10.1158/1055-9965.EPI-09-0291

Li CI, Mathes RW, Bluhm EC, et al. Migraine history and breast cancer risk among postmenopausal women. J Clin Oncol. 2010 Feb 20;28(6):1005-10. doi: 10.1200/JCO.2009.25.0423. Epub 2010 Jan 25.

Phipps AI, Anderson GL, Cochrane BB, et al. Migraine history, nonsteroidal antiinflammatory drug use, and risk of postmenopausal endometrial cancer. Horm Cancer. 2012 Dec;3(5-6):240-8. doi: 10.1007/s12672012-0117-7. Epub 2012 Jul 24.

Nappi RE, Tiranini L, Sacco S, et al. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355

Rustichelli C, Bellei E, Bergamini S, et al. Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study. Cephalalgia. 2020 Oct;40(12):1355-62. doi: 10.1177/0333102420937742. Epub 2020 Jun 26.

Mattsson P. Serum levels of androgens and migraine in postmenopausal women. Clin Sci (Lond). 2002 Nov;103(5):487-91. doi: 10.1042/cs1030487

Табеева ГР. Головные боли в общеврачебной практике. Терапевтический архив. 2022;94(1):114-21. doi: 10.26442/00403660.2022.01.20

Tabeeva GR. Headaches in general medical practice. Terapevticheskiy arkhiv = Therapeutic Archive. 2022;94(1):114-21. doi: 10.26442/00403660.2022.01.201325 (In Russ.).

Farkouh ME, Greenberg BP. An evidencebased review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009 May 1;103(9):1227-37. doi: 10.1016/j.amjcard.2009.01.014

Curtis WD, Griffin JW. Non-steroidal antiinflammatory drug-induced gastroduodenal injury: therapeutic recommendations. Aliment Pharmacol Ther. 1991;5 Suppl 1:99-109. doi: 10.1111/j.1365-2036.1991.tb00753.x

Süleyman H, Demircan B, Karagöz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep. 2007 MayJun;59(3):247-58.

Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015 Feb;35(2):118-31. doi: 10.1177/0333102414550416. Epub 2014 Sep 22.

Pavlovic JM. Evaluation and management of migraine in midlife women. Menopause. 2018 Aug;25(8):927-9. doi: 10.1097/GME.0000000000001104

Musson DG, Birk KL, Panebianco DL, et al. Pharmacokinetics of rizatriptan in healthy elderly subjects. Int J Clin Pharmacol Ther. 2001 Oct;39(10):447-52.

Peck RW, Seaber EJ, Dixon RM, et al. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin Pharmacol Ther. 1998 Mar;63(3):342-53. doi: 10.1016/S0009-9236(98)90166-7

Kaniecki R. Neuromodulators for migraine prevention. Headache. 2008 Apr;48(4):586-600. doi: 10.1111/j.1526-4610.2007.01040.x. Epub 2008 Jan 18.

Robbins MS, Lipton RB. Management of headache in the elderly. Drugs Aging. 2010 May;27(5):377-98. doi: 10.2165/11315980000000000-00000

Ibor JJ, Carrasco JL, Prieto R, Garcia-Calvo C; Ceres Study Group. Effectiveness and safety of venlafaxine extended release in elderly depressed patients. Arch Gerontol Geriatr. 2008 May-Jun;46(3):317-26. doi: 10.1016/j.archger.2007.05.005. Epub 2007 Jul 6.

Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-45. doi: 10.1111/j.1526-4610.2012.02185.x

Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019 May;40(Suppl 1):99105. doi: 10.1007/s10072-019-03769-8

Сергеев АВ, Табеева ГР, Филатова ЕГ и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов Российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116

Sergeev AV, Tabeeva GR, Filatova EG, et al. Application of a new biological pathogenetic therapy of migraine in clinical practice: expert consensus of the Russian Headache Research Society. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(5):109-16. doi: 10.14412/2074-2711-2022-5-109-116 (In Russ.).

Головачева ВА, Головачева АА, Парфенов ВА и др. Когнитивно-поведенческая терапия в лечении хронической мигрени: описание клинического случая. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):7480. doi: 10.14412/2074-2711-2021-1-74-80

Golovacheva VA, Golovacheva AA, Parfenov VA, et al. Cognitive behavioral therapy in the treatment of chronic migraine: a clinical case report. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(1):74-80. doi: 10.14412/2074-27112021-1-74-80 (In Russ.).

Головачева ВА. Лечение хронической мигрени и инсомнии с помощью когнитивно-поведенческой терапии. Медицинский совет. 2023;(3):68-76. doi: 10.21518/ms2023-080

Golovacheva VA. Treatment of chronic migraine and insomnia with cognitive behavioral therapy. Meditsinskiy sovet = Medical Council. 2023;(3):68-76. doi: 10.21518/ms2023080 (In Russ.).

Tiseo C, Vacca A, Felbush A, et al; European Headache Federation School of Advanced Studies (EHF-SAS). Migraine and sleep disorders: a systematic review. J Headache Pain. 2020 Oct 27;21(1):126. doi: 10.1186/s10194-020-01192-5

Amin FM, Aristeidou S, Baraldi C, et al; European Headache Federation School of Advanced Studies (EHF-SAS). The association between migraine and physical exercise. J Headache Pain. 2018 Sep 10;19(1):83. doi: 10.1186/s10194-018-0902-y

Denche-Zamorano A, Paredes-Mateos V, Pastor-Cisneros R, et al. Physical Activity Level, Depression, Anxiety, and Self-Perceived Health in Spanish Adults with Migraine: A Cross-Sectional Study. Int J Environ Res Public Health. 2022 Oct 25;19(21):13882. doi: 10.3390/ijerph192113882

Hodson J, Thompson J, al-Azzawi F. Headache at menopause and in hormone replacement therapy users. Climacteric. 2000 Jun;3(2):119-24. doi: 10.3109/13697130009167613

Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas. 2001 Apr 20;38(2):157-63. doi: 10.1016/s03785122(00)00215-2

Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002 Oct;42(9):924-9. doi: 10.1046/j.15264610.2002.02215.x. Erratum in: Headache. 2003 Feb;43(2):172. Erratum in: Headache. 2003 Mar;43(3):310.

Misakian AL, Langer RD, Bensenor IM, et al. Postmenopausal hormone therapy and migraine headache. J Womens Health (Larchmt). 2003 Dec;12(10):1027-36. doi: 10.1089/154099903322643956

Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol. 2007 Jan;14(1):73-8. doi: 10.1111/j.14681331.2006.01557.x

Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321

Кирьянова ЕА, Табеева ГР. Гормональная терапия менструально-ассоциированной мигрени: за и против. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):6975. doi: 10.14412/2074-2711-2022-1-69-75

Kiryanova EA, Тabeeva GR. Hormone therapy for menstrual-associated migraine: pros and cons. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):69-75. doi: 10.14412/2074-2711-2022-1-69-75 (In Russ.).

Sahni S, Lobo-Romero A, Smith T. Contemporary Non-hormonal Therapies for the Management of Vasomotor Symptoms Associated with Menopause: A Literature Review. touchREV Endocrinol. 2021 Nov;17(2):133-7. doi: 10.17925/EE.2021.17.2.133. Epub 2021 Oct 13.

Артымук НВ, Тачкова ОА, Марочко ТЮ. Современные подходы к управлению менопаузой. Гинекология. 2021;23(2):137-43. doi: 10.26442/20795696.2021.1.200691

Artymuk NV, Tachkova OA, Marochko TYu. Modern approaches to the management of menopause. Gynecology. 2021;23(2):137-43. doi: 10.26442/20795696.2021.1.200691 (In Russ.).

The authors declare that there are no conflicts of interest present.